Lyell Immunopharma, Inc. Common Stock (LYEL) is a publicly traded Healthcare sector company. As of July 18, 2026, LYEL trades at $13.34 with a market cap of $340.37M and a P/E ratio of -0.98. LYEL moved -3.96% today. Year to date, LYEL is -56.73%; over the trailing twelve months it is +39.92%. Its 52-week range spans $7.65 to $45.00. Analyst consensus is buy with an average price target of $37.50. Rallies surfaces LYEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lyell Immunopharma, Inc. Common Stock (LYEL) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. LYEL moved -3.96% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $13.34 |
| Market Cap | $340.37M |
| P/E Ratio | -0.98 |
| EPS | $-13.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $45.00 |
| 52-Week Low | $7.65 |
| Volume | 155.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $31.00K |
| Net Income | $-246.41M |
| Gross Margin | 0.00% |
4 analysts cover LYEL: 0 strong buy, 3 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $37.50.